Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;28(2):519-522.
doi: 10.1038/s41391-024-00896-y. Epub 2024 Sep 21.

Trends in pre-biopsy MRI usage for prostate cancer detection, 2007-2022

Simon John Christoph Soerensen  1   2 , Shufeng Li  3   4 , Marvin E Langston  5 , Richard E Fan  3 , Mirabela Rusu #  3   6   7 , Geoffrey A Sonn #  3   6
Affiliations

Trends in pre-biopsy MRI usage for prostate cancer detection, 2007-2022

Simon John Christoph Soerensen et al. Prostate Cancer Prostatic Dis. 2025 Jun.

Abstract

Background: Clinical guidelines favor MRI before prostate biopsy due to proven benefits. However, adoption patterns across the US are unclear.

Methods: This study used the Merative™ Marketscan® Commercial & Medicare Databases to analyze 872,829 prostate biopsies in 726,663 men from 2007-2022. Pre-biopsy pelvic MRI within 90 days was the primary outcome. Descriptive statistics and generalized estimating equations assessed changes over time, urban-rural differences, and state-level variation.

Results: Pre-biopsy MRI utilization increased significantly from 0.5% in 2007 to 35.5% in 2022, with faster adoption in urban areas (36.1% in 2022) versus rural areas (28.3% in 2022). Geographic disparities were notable, with higher utilization in California, New York, and Minnesota, and lower rates in the Southeast and Mountain West.

Conclusions: The study reveals a paradigm shift in prostate cancer diagnostics towards MRI-guided approaches, influenced by evolving guidelines and clinical evidence. Disparities in access, particularly in rural areas and specific regions, highlight the need for targeted interventions to ensure equitable access to advanced diagnostic techniques.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Temporal trends in pre-biopsy MRI for prostate cancer diagnosis in the United States, and in urban and rural areas, 2007–2022.
Left panel highlights overall yearly rates. Right panel highlights yearly rates in urban and rural areas.
Fig. 2
Fig. 2. Geographic trends in pre-biopsy MRI for prostate cancer diagnosis in the United States, 2007–2022.
A 2007–2010, B 2011–2014, C 2015–2018, and D 2019–2022. Information on states with fewer than 11 MRI-guided biopsies in each time period has been omitted.
See this image and copyright information in PMC

References

    1. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378:1767–77. - PMC - PubMed
    1. Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multi-parametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20:100–9. - PubMed
    1. van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, et al. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol. 2019;75:570–8. - PubMed
    1. Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020;382:917–28. - PMC - PubMed
    1. Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, et al. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023: Featured Updates to the NCCN Guidelines. J Natl Compr Cancer Netw. 2023;21:236–46. - PubMed

LinkOut - more resources